Detection of Rheumatoid Arthritis–Interstitial Lung Disease Is Enhanced by Serum Biomarkers
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
RATIONALE: Interstitial lung disease (ILD), a leading cause of morbidity and mortality in rheumatoid arthritis (RA), is highly prevalent, yet RA-ILD is underrecognized. OBJECTIVES: To identify clinical risk factors, autoantibodies, and biomarkers associated with the presence of RA-ILD. METHODS: Subjects enrolled in Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study (BRASS) and American College of Rheumatology (ACR) cohorts were evaluated for ILD. Regression models were used to assess the association between variables of interest and RA-ILD. Receiver operating characteristic curves were generated in BRASS to determine if a combination of clinical risk factors and autoantibodies can identify RA-ILD and if the addition of investigational biomarkers is informative. This combinatorial signature was subsequently tested in ACR. MEASUREMENTS AND MAIN RESULTS: A total of 113 BRASS subjects with clinically indicated chest computed tomography scans (41% with a spectrum of clinically evident and subclinical RA-ILD) and 76 ACR subjects with research or clinical scans (51% with a spectrum of RA-ILD) were selected. A combination of age, sex, smoking, rheumatoid factor, and anticyclic citrullinated peptide antibodies was strongly associated with RA-ILD (areas under the curve, 0.88 for BRASS and 0.89 for ACR). Importantly, a combinatorial signature including matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D significantly increased the areas under the curve to 0.97 (P = 0.002, BRASS) and 1.00 (P = 0.016, ACR). Similar trends were seen for both clinically evident and subclinical RA-ILD. CONCLUSIONS: Clinical risk factors and autoantibodies are strongly associated with the presence of clinically evident and subclinical RA-ILD on computed tomography scan in two independent RA cohorts. A biomarker signature composed of matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D significantly strengthens this association. These findings may facilitate identification of RA-ILD at an earlier stage, potentially leading to decreased morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752 · cited 2×
“94 95 96 Abstract word count: 248 / 250 97 98 Key words for use as indexing terms: interstitial lung disease (ILD), rheumatoid arthritis (RA), 99 subclinical, biomarkers, risk prediction 100 101 102 Copyright © 2015 by the American Thoracic Society 3 Introduction 103 Rheumatoid arthritis (RA),(1) a highly prevalent sy…”
InfluentialAletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27584 · Cited by 9,619
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Scott, D. L., Wolfe, F., & Huizinga, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60826-4 · Cited by 3,013
Steyerberg, E. W. (2009) · Statistics for Biology and Health · doi:10.1007/978-0-387-77244-8 · Cited by 1,491
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E., Mudano, A., Pisu, M., Elkins‐Melton, M., et al. (2008) · Arthritis Care & Research · doi:10.1002/art.23721 · Cited by 1,157
Bongartz, T., Nannini, C., Medina‐Velasquez, Y. F., Achenbach, S. J., Crowson, C. S., Ryu, J. H., Vassallo, R., Gabriel, S. E., & Matteson, E. L. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27405 · Cited by 864
Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities
Washko, G. R., Hunninghake, G. M., Fernandez, I. E., Nishino, M., Okajima, Y., Yamashiro, T., Ross, J. C., Estépar, R. S. J., Lynch, D. A., Brehm, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007285 · Cited by 611
Self-citationMMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 588
Self-citationPredicting Survival Across Chronic Interstitial Lung Disease
Ryerson, C. J., Vittinghoff, E., Ley, B., Lee, J. S., Mooney, J. J., Jones, K. D., Elicker, B. M., Wolters, P. J., Koth, L. L., King, T. E., et al. (2014) · Chest · doi:10.1378/chest.13-1474 · Cited by 558
Kelly, C. A., Saravanan, V., Nisar, M., Arthanari, S., Woodhead, F. A., Price-Forbes, A. N., Dawson, J., Sathi, N., Ahmad, Y., Koduri, G., et al. (2014) · Rheumatology · doi:10.1093/rheumatology/keu165 · Cited by 549
Rheumatoid Arthritis–Interstitial Lung Disease–associated Mortality
Olson, A. L., Swigris, J. J., Sprunger, D. B., Fischer, A., Fernandez-Perez, E. R., Solomon, J., Murphy, J., Cohen, M., Raghu, G., & Brown, K. K. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201004-0622oc · Cited by 544
MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities
Hunninghake, G. M., Hatabu, H., Okajima, Y., Gao, W., Dupuis, J., Latourelle, J. C., Nishino, M., Araki, T., Zazueta, O. E., Kurugol, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1216076 · Cited by 456
Self-citationInterstitial Lung Disease in Recent Onset Rheumatoid Arthritis
GABBAY, E., TARALA, R., WILL, R., CARROLL, G., ADLER, B., CAMERON, D., & LAKE, F. R. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.156.2.9609016 · Cited by 451
Progressive Preclinical Interstitial Lung Disease in Rheumatoid Arthritis
Gochuico, B. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.59 · Cited by 409 · cited 2×
“population.(5, 6, 8, 9) Subclinical disease(10) (no previous ILD diagnosis but interstitial lung 114 abnormalities (ILA)(11) on CT) is present in an additional 30% of individuals,(7, 9) with 34-57% 115 demonstrating radiologic progression over 1-2 years.”
Rheumatoid Arthritis-Associated Interstitial Lung Disease
Kim, E. J., Collard, H. R., & King, T. E. (2009) · Chest · doi:10.1378/chest.09-0444 · Cited by 404
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0058oc · Cited by 381
Young, A., Koduri, G., Batley, M., Kulinskaya, E., Gough, A., Norton, S., Dixey, J., & on behalf of the Early Rheumatoid Arthritis Study (ERAS) group (2006) · Rheumatology · doi:10.1093/rheumatology/kel253 · Cited by 354
Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis
Prasse, A., Probst, C., Bargagli, E., Zissel, G., Toews, G. B., Flaherty, K. R., Olschewski, M., Rottoli, P., & Müller-Quernheim, J. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200808-1201oc · Cited by 328
Serum surfactant proteins‐A and ‐D as biomarkers in idiopathic pulmonary fibrosis
Greene, K. E., King, T. E., Kuroki, Y., Bucher-Bartelson, B., Hunninghake, G. W., Newman, L. S., Nagae, H., & Mason, R. J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00081102 · Cited by 316
Self-citationCigarette smoking and rheumatoid arthritis severity
Saag, K. G., Cerhan, J. R., Kolluri, S., Ohashi, K., Hunninghake, G. W., & Schwartz, D. A. (1997) · Annals of the Rheumatic Diseases · doi:10.1136/ard.56.8.463 · Cited by 302
Self-citationTAKAHASHI, H., FUJISHIMA, T., KOBA, H., MURAKAMI, S., KUROKAWA, K., SHIBUYA, Y., SHIRATORI, M., KUROKI, Y., & ABE, S. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9910080 · Cited by 291
Stears, R. L., Martinsky, T., & Schena, M. (2003) · Nature Medicine · doi:10.1038/nm0103-140 · Cited by 279
Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer
Gorelik, E., Landsittel, D. P., Marrangoni, A. M., Modugno, F., Velikokhatnaya, L., Winans, M. T., Bigbee, W. L., Herberman, R. B., & Lokshin, A. E. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0404 · Cited by 264
Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities
Saag, K. G., Kolluri, S., Koehnke, R. K., Georgou, T. A., Rachow, J. W., Hunninghake, G. W., & Schwartz, D. A. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391014 · Cited by 238
Self-citationIdentification of Early Interstitial Lung Disease in Smokers from the COPDGene Study
Washko, G. R., Lynch, D. A., Matsuoka, S., Ross, J. C., Umeoka, S., Diaz, A., Sciurba, F. C., Hunninghake, G. M., San José Estépar, R., Silverman, E. K., et al. (2010) · Academic Radiology · doi:10.1016/j.acra.2009.07.016 · Cited by 232
Self-citationPrasse, A., Pechkovsky, D. V., Toews, G. B., Schäfer, M., Eggeling, S., Ludwig, C., Germann, M., Kollert, F., Zissel, G., & Müller‐Quernheim, J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22559 · Cited by 227
Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., McCormack, F. X., Ix, J. H., Kervitsky, A., Schwarz, M. I., & King, T. E. (2009) · Chest · doi:10.1378/chest.08-2209 · Cited by 209
Roger S. Mitchell Lecture. Rheumatoid Lung Disease
Brown, K. K. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200703-045ms · Cited by 196
Predictors of mortality in rheumatoid arthritis‐related interstitial lung disease
Assayag, D., Lubin, M., Lee, J. S., King, T. E., Collard, H. R., & Ryerson, C. J. (2014) · Respirology · doi:10.1111/resp.12234 · Cited by 195
Risk factors for the development of rheumatoid arthritis
Oliver, J. E., & Silman, A. J. (2006) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740600718080 · Cited by 175
Subclinical Interstitial Lung Disease: Why You Should Care
Doyle, T. J., Hunninghake, G. M., & Rosas, I. O. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1420pp · Cited by 166 · cited 3×
“population.(5, 6, 8, 9) Subclinical disease(10) (no previous ILD diagnosis but interstitial lung 114 abnormalities (ILA)(11) on CT) is present in an additional 30% of individuals,(7, 9) with 34-57% 115 demonstrating radiologic progression over 1-2 years.”
Self-citationThe influence of sex on the phenotype of rheumatoid arthritis
Weyand, C. M., Schmidt, D., Wagner, U. G., & Goronzy, J. J. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199805)41:5<817::aid-art7>3.0.co;2-s · Cited by 165
Blood Biomarkers MMP-7 and SP-A
Song, J. W., Do, K., Jang, S. J., Colby, T. V., Han, S., & Kim, D. S. (2013) · CHEST Journal · doi:10.1378/chest.11-2735 · Cited by 154
Biomarkers of Rheumatoid Arthritis–Associated Interstitial Lung Disease
Chen, J., Doyle, T. J., Liu, Y., Aggarwal, R., Wang, X., Shi, Y., Ge, S., Huang, H., Lin, Q., Liu, W., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38904 · Cited by 146
Self-citationDawson, J., Fewins, H. E., Desmond, J., Lynch, M. P., & Graham, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.6.517 · Cited by 145
Assayag, D., Elicker, B. M., Urbania, T. H., Colby, T. V., Kang, B. H., Ryu, J. H., King, T. E., Collard, H. R., Kim, D. S., & Lee, J. S. (2013) · Radiology · doi:10.1148/radiol.13130187 · Cited by 144
Interstitial Lung Abnormalities and Reduced Exercise Capacity
Doyle, T. J., Washko, G. R., Fernandez, I. E., Nishino, M., Okajima, Y., Yamashiro, T., Divo, M. J., Celli, B. R., Sciurba, F. C., Silverman, E. K., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201109-1618oc · Cited by 144
Self-citationHarlow, L. A., Rosas, I. O., Gochuico, B. R., Mikuls, T. R., Dellaripa, P. F., Oddis, C. V., & Ascherman, D. P. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37881 · Cited by 137
Self-citationFunctional Impact of a Spectrum of Interstitial Lung Abnormalities in Rheumatoid Arthritis
Doyle, T. J., Dellaripa, P. F., Batra, K. L., Frits, M. L., Iannaccone, C. K., Hatabu, H., Nishino, M., Weinblatt, M. E., Ascherman, D. P., Washko, G. R., et al. (2013) · CHEST Journal · doi:10.1378/chest.13-1394 · Cited by 108 · cited 2×
“progression could lead to a meaningful change in clinical outcomes given the availability of 359 numerous DMARDS, biologics(3) and novel anti-fibrotic therapies(46).”
Self-citationIannaccone, C. K., Lee, Y. C., Cui, J., Frits, M. L., Glass, R. J., Plenge, R. M., Solomon, D. H., Weinblatt, M. E., & Shadick, N. A. (2010) · Rheumatology · doi:10.1093/rheumatology/keq263 · Cited by 104
Self-citationDoyle, T. J., Lee, J. S., Dellaripa, P. F., Lederer, J. A., Matteson, E. L., Fischer, A., Ascherman, D. P., Glassberg, M. K., Ryu, J. H., Danoff, S. K., et al. (2014) · CHEST Journal · doi:10.1378/chest.13-2408 · Cited by 100
Self-citationSurfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis.
Barlo, N. P., van Moorsel, C. H. M., Ruven, H. J. T., Zanen, P., van den Bosch, J. M. M., & Grutters, J. C. (2009) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 99
Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis
Inui, N., Enomoto, N., Suda, T., Kageyama, Y., Watanabe, H., & Chida, K. (2008) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2008.06.014 · Cited by 81
The Age of Idiopathic Pulmonary Fibrosis
Collard, H. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0049ed · Cited by 75 · cited 2×
“disease (ILD) is present on the computed tomography (CT) scans of 30-60% of RA patients(5-7) 109 and is the only complication of RA increasing in prevalence.”
Interstitial Lung Disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases
Rosas, I. O., Dellaripa, P. F., Lederer, D. J., Khanna, D., Young, L. R., & Martínez, F. J. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201312-429ld · Cited by 49
Self-citationThe Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases
Doyle, T. J., Pinto-Plata, V., Morse, D., Celli, B. R., & Rosas, I. O. (2012) · CHEST Journal · doi:10.1378/chest.12-1540 · Cited by 36
Self-citationShadick, N. A., Heller, J. E., Weinblatt, M. E., Maher, N. E., Cui, J., Ginsburg, G. S., Coblyn, J. S., Anderson, R., Solomon, D. H., Roubenoff, R., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067603 · Cited by 24 · cited 1×
“3 Introduction 103 Rheumatoid arthritis (RA),(1) a highly prevalent systemic connective tissue disease, 104 currently affects approximately 1.”
Self-citation
Cited by
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis
Conforti, A., Di Cola, I., Pavlych, V., Ruscitti, P., Berardicurti, O., Ursini, F., Giacomelli, R., & Cipriani, P. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102735 · Cited by 407
Kadura, S., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0011-2021 · Cited by 328
C-reactive protein and implications in rheumatoid arthritis and associated comorbidities
Pope, J. E., & Choy, E. H. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.11.005 · Cited by 320
The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease
Spagnolo, P., Lee, J. S., Sverzellati, N., Rossi, G., & Cottin, V. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40574 · Cited by 306
Surfactant Protein D in Respiratory and Non-Respiratory Diseases
Sorensen, G. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00018 · Cited by 219
“In some cases, the association between circulatory SP-D and extrapulmonary disease may be partly explained by the coexistence of respiratory disease or the pulmonary effects of disease (430) (431) (432) (433) (434) .”
Background
Metadata
- Authors
- Doyle, T. J., Patel, A. S., Hatabu, H., Nishino, M., Wu, G., Osorio, J. C., Golzarri, M. F., Traslosheros, A., Chu, S. G., Frits, M. L., Iannaccone, C. K., Koontz, D., Fuhrman, C., Weinblatt, M. E., El-Chemaly, S. Y., Washko, G. R., Hunninghake, G. M., Choi, A. M. K., Dellaripa, P. F., Oddis, C. V., Shadick, N. A., Ascherman, D. P., & Rosas, I. O.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-06-15
- Volume
- 191
- Issue
- 12
- Pages
- 1403-1412
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2004762925
- Cited by
- 215
- References
- 51
- FWCI
- 6.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.